At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Parsaclisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Phase 2 Study of INCB050465 in Participants With Primary Sjögren's Syndrome
In Brief
A Phase 2 clinical trial evaluating Parsaclisib for Primary Sjögren's Syndrome. Completed, enrolled 10 participants across 4 sites.
Detailed Summary
The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of Sjögren's syndrome (SS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Sjögren's Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartFeb 2019
Primary CompletionDec 2019
Study CompletionJan 2020
TodayJul 2026
First PostedAug 13, 2018
Enrollment StartFeb 28, 2019
Primary CompletionDec 7, 2019
Study CompletionJan 2, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.9 years ago
Interventions
Parsaclisibdrug
Parsaclisib administered orally once daily at the protocol-defined dose.